REFERENCES
1 Alffenaar J-WC, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010;49:559–65. doi:10.2165/11532080-000000000-00000
2 Alliance G, Development TBD, Alliance TB, et al. Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children. WHO 2017;:0–1.
3 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839–54. doi:10.1007/s40265-014-0222-8
4 Anon. Prothionamide. Tuberculosis (Edinb) 2008;88:139–40. doi:10.1016/S1472-9792(08)70020-9
5 Anon. Rifapentine. Tuberculosis (Edinb) 2008;88:155–8. doi:10.1016/S1472-9792(08)70025-8
6 Anon. Levofloxacin. Tuberculosis (Edinb) 2008;88:119–21. doi:10.1016/S1472-9792(08)70013-1
7 Anon. Moxifloxacin. Tuberculosis (Edinb) 2008;88:127–31. doi:10.1016/S1472-9792(08)70016-7
8 Anon. Clofazimine. Tuberculosis (Edinb) 2008;88:96–9. doi:10.1016/S1472-9792(08)70006-4
9 Anon. Cycloserine. Tuberculosis (Edinb) 2008;88:100–1. doi:10.1016/S1472-9792(08)70007-6
10 Anon. TMC-207. Tuberculosis (Edinb) 2008;88:168–9. doi:10.1016/S1472-9792(08)70029-5
11 Anon. A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong. Tubercle 1968;49:243–80.http://www.ncbi.nlm.nih.gov/pubmed/4179210 (accessed 4 Sep2013).
12 Anon. Clarithromycin. Tuberculosis (Edinb) 2008;88:92–5. doi:10.1016/S1472-9792(08)70005-2
13 Anon. Ethambutol. Tuberculosis (Edinb) 2008;88:102–5. doi:10.1016/S1472-9792(08)70008-8
14 Anon. Rifampin. Tuberculosis (Edinb) 2008;88:151–4. doi:10.1016/S1472-9792(08)70024-6
15 Anon. Capreomycin. Tuberculosis (Edinb) 2008;88:89–91. doi:10.1016/S1472-9792(08)70004-0
16 Anon. Para-aminosalicylic acid. Tuberculosis (Edinb) 2008;88:137–8. doi:10.1016/S1472-9792(08)70019-2
17 Anon. Pyrazinamide. Tuberculosis (Edinb) 2008;88:141–4. doi:10.1016/S1472-9792(08)70021-0
18 Anon. Linezolid. Tuberculosis (Edinb) 2008;88:122–5. doi:10.1016/S1472-9792(08)70014-3
19 Anon. Streptomycin. Tuberculosis (Edinb) 2008;88:162–3. doi:10.1016/S1472-9792(08)70027-1
20 Anon. Amikacin. Tuberculosis (Edinb) 2008;88:87–8. doi:10.1016/S1472-9792(08)70003-9
21 Anon. Isoniazid. Tuberculosis (Edinb) 2008;88:112–6. doi:10.1016/S1472-9792(08)70011-8
22 Anon. Rifabutin. Tuberculosis (Edinb) 2008;88:145–7. doi:10.1016/S1472-9792(08)70022-2
23 Ashley, C and Currie A, editor. The Renal Drug Handbook. 3rd ed. Radcliffe Medical Press, Oxford 2009.
24 ASHP. AHFS Drug Information. Am. Soc. Heal. Pharm. Bathesda, USA. 2011.
25 Auclair B, Nix DE, Adam RD, et al. Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids. Antimicrob Agents Chemother 2001;45:810–4. doi:10.1128/AAC.45.3.810
26 Aventis. Priftin® (rifapentine) tablets prescribing information (dated Feb 2002). In: Montvale N, ed. Physicians’ desk reference 5th edition. Medical Economics Company Inc 2003. 763–6.
27 Banerjee S, Narayanan M, Gould K. Monitoring aminoglycoside level. BMJ 2012;345:e6354.http://www.ncbi.nlm.nih.gov/pubmed/23044986 (accessed 24 Aug2013).
28 Black HR, Griffith RS, Peabody AM. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann N Y Acad Sci 1966;135:974–82.http://www.ncbi.nlm.nih.gov/pubmed/5220250 (accessed 19 Aug2013).
29 Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015;191:1058–65. doi:10.1164/rccm.201407-1264OC
30 Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 2016;3099:1–11. doi:10.1016/S1473-3099(16)30274-2
31 Bolhuis MS, van Altena R, Uges DRA, et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010;54:5418–9. doi:10.1128/AAC.00757-10
32 Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013;42:1614–21. doi:10.1183/09031936.00001913
33 Cabrera-rivero JL, Vargas-vasquez DE, Gao M, et al. new england journal. 2012;:2151–60.
34 Caminero JA. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013. Int Union Against Tuberc Lung Dis 2013.
35 Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005;49:2816–21. doi:10.1128/AAC.49.7.2816-2821.2005
36 Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994;3:267–74. doi:10.1016/0924-8579(94)90054-X
37 Chaulet P, Raviglione M, Bustreo F. Epidemiology, control and treatment of multidrug-resistant tuberculosis. Drugs 1996;52 Suppl 2:103-7-8.http://www.ncbi.nlm.nih.gov/pubmed/8869846 (accessed 19 Aug2013).
38 Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity--a case report. Lepr Rev 1995;66:63–8.http://www.ncbi.nlm.nih.gov/pubmed/7731343 (accessed 6 Nov2013).
39 Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447–54. doi:10.5588/ijtld.11.0451
40 Dannemann B, Bakare N, Marez T De, et al. QTcF prolongation in a Phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine. 52nd Intersci Conf Antimicrob Agents Chemother 2012.
41 Dauby N, Muylle I, Mouchet F, et al. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011;30:812–3. doi:10.1097/INF.0b013e3182154b05
42 De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013;41:1386–92. doi:10.1183/09031936.00124312
43 Devine B. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650–655.
44 Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284–93. doi:10.1093/jac/dks389
45 Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284–93. doi:10.1093/jac/dks389
46 Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271–6. doi:10.1128/AAC.06126-11
47 Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986–93. doi:10.1016/S0140-6736(12)61080-0
48 Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723–32. doi:10.1056/NEJMoa1313865
49 Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397–405. doi:10.1056/NEJMoa0808427
50 Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001;33:466–9.http://www.ncbi.nlm.nih.gov/pubmed/11450868 (accessed 24 Aug2013).
51 Durrant JD, Campbell K FS et al. Ototoxicity Monitoring. 2009. http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines.pdf
52 Dutta BS, Hassan G, Waseem Q, et al. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis 2012;16:141. doi:10.5588/ijtld.11.0388
53 Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516–28. doi:10.1183/09031936.00073611
54 Garcia-Prats, AJ Donald, PR Hesseling, AC Schaaf H. Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines. World Heal Organ Published Online First: 2013.www.who.int/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf
55 Goh TL, Towns CR, Jones KL, et al. Extensively drug-resistant tuberculosis: New Zealand’s first case and the challenges of management in a low-prevalence country. Med J Aust 2011;194:602–4.http://www.ncbi.nlm.nih.gov/pubmed/21644877 (accessed 24 Aug2013).
56 Gonzalo X, Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 2013;68:366–9. doi:10.1093/jac/dks395
57 Gordin F, Bliven-sizemore E, Hackman J, et al. new england journal. 2011;:2155–66.
58 Gynaecology RC of O and. Drug Interactions with Hormonal Contraception. Faculty of Sexual & Reproductive Healthcare Clinical Guidance 2011. http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf
59 Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis 2008;12:967–71.http://www.ncbi.nlm.nih.gov/pubmed/18647459 (accessed 21 Feb2017).
60 Hoc A, Management A, Ototoxic R, et al. Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy. Published Online First: March 1994. doi:10.1044/policy.GL1994-00003
61 Hutchison TA SD& AM. Drugdex System Internet version Micromedex Inc. Greenwood Village, Colorado.
62 Janssen. Compassionate Use Program of TMC207 in Patients with Extensively Drug Resistant (XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection. Guidel physicians Pharm 2012.
63 Janssen. Anti-Infective Drugs Advisory Committee Meeting Briefing Document: TMC207 (bedaquiline): Treatment of Patients with MDR-TB. NDA 2012;:204–384.
64 Janssen. SirturoTM U.S. Food and Drug Administration bedaquiline package insert. 2012.http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html
65 Jindani A, Harrison TS, Nunn AJ, et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med 2014;371:1599–608. doi:10.1056/NEJMoa1314210
66 Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139–45.http://www.ncbi.nlm.nih.gov/pubmed/18230245 (accessed 4 Sep2013).
67 Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508–18. doi:10.1056/NEJMoa1201964
68 Lee M, Song T, Kim Y, et al. Linezolid for XDR-TB — Final Study Outcomes. N Engl J Med 2015;373:290–1. doi:10.1056/NEJMc1500286
69 Lehmann CR, Garrett LE, Winn RE, et al. Capreomycin kinetics in renal impairment and clearance by hemodialysis. Am Rev Respir Dis 1988;138:1312–3. doi:10.1164/ajrccm/138.5.1312
70 Loeffler A et al. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd ed. Curry International Tuberculosis Center and California Department of Public Health 2011.
71 Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34:387–93. doi:10.1183/09031936.00009509
72 Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557–70. doi:10.1136/thx.2009.133173
73 National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. 2011.
74 Organisation WH. Interim guidance on the use of bedaquiline to treat MDR-TB. World Heal Organ 2012;:WHO/HTM/TB/2013.6.
75 Orgnaisation WH. Statement on the position of the stop TB department with regard to thioacetazone + isoniazid within context of the who model list of essential medicines. World Heal. Organ. 2004.http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf
76 Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012;16:558–60. doi:10.5588/ijtld.11.0414
77 Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253–62.http://www.ncbi.nlm.nih.gov/pubmed/8231410 (accessed 19 Aug2013).
78 Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999;159:932–4. doi:10.1164/ajrccm.159.3.9807131
79 Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169–83.http://www.ncbi.nlm.nih.gov/pubmed/12381217 (accessed 4 Sep2013).
80 Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538–44. doi:10.1086/420742
81 PfizerTrecator®. U.S. Physician Prescribing Information. PfizerTrecator®. 2007;:1–8.http://labeling.pfizer.com/showlabeling.aspx?id=473 (accessed 28 Aug2013).
82 Pharmaceuticals K. Personal communication: Capreomycin and intravenous administration.
83 Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011;38:888–94. doi:10.1183/09031936.00176610
84 Prasad R, Verma SK, Sahai S, et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci;48:183–6.http://www.ncbi.nlm.nih.gov/pubmed/18610675 (accessed 24 Aug2013).
85 Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012;16:1588–93. doi:10.5588/ijtld.12.0322
86 Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27–35. doi:10.1016/S1473-3099(12)70264-5
87 Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831–5. doi:10.1128/AAC.01204-07
88 Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011;12:31–8. doi:10.1016/j.prrv.2010.09.010
89 Schilling R. Appropriate monitoring for prolonged QT. Unpubl Commun 2013.
90 Seddon J a, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012;186:953–64. doi:10.1164/rccm.201206-1001CI
91 Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393–400. doi:10.1183/09031936.00125812
92 Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430–42. doi:10.1183/09031936.00022912
93 Soumakis SA, Berg D, Harris HW. Hypothyroidism in a Patient Receiving Treatment for Multidrug‐Resistant Tuberculosis. Clin Infect Dis 1998;27:910–1. doi:10.1086/517171
94 Srivastava S, Peloquin C a, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449–53. doi:10.1183/09031936.00073213
95 STOP TB Partnership Child Health Subgroup WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children. Int J Tuberc Lung Dis 2006;10:1205–11.http://www.ncbi.nlm.nih.gov/pubmed/17131777 (accessed 4 Sep2013).
96 STOP TB Partnership, Child Health Subgroup, World Health Organisation, Geneva S. Rapid advice: Treatment of Tuberculosis in Children. WHO 2010;:WHO/HTM/TB/2010.13.
97 Sturdy A, Goodman A, José RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815–20. doi:10.1093/jac/dkr221
98 Sweetman S M, editor. The Complete Drug Reference, online edition. Pharm. Press. London.
99 Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45:161–70. doi:10.1183/09031936.00035114
100 Thee S, Seifart HI, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother 2011;55:4594–600. doi:10.1128/AAC.00379-11
101 Thee S, Zöllner EW, Willemse M, et al. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011;15:1191–3, i. doi:10.5588/ijtld.10.0707
102 Tucker H. Dear Healthcare Professional Letter. 2005.http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164879.pdf
103 WHO. Guidelines on the management of latent tuberculosis infection. World Heal Organ 2015;WHO/HTM/TB.http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1&ua=1
104 WHO. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva World Heal Organ Published Online First: 2013.http://www.ncbi.nlm.nih.gov/books/NBK154134/
105 WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis: An interim policy guidance. World Heal Organ Published Online First: 2014.http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1
106 WHO. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. World Heal Organ 2006;:WHO/HTM/ TB/2006.371, WHO/FCH/CAH/2006.7.
107 WHO. STATEMENT ON THE POSITION OF THE STOP TB DEPARTMENT WITH REGARD TO THIOACETAZONE + ISONIAZID WITHIN CONTEXT OF THE WHO MODEL LIST OF ESSENTIAL MEDICINES. WHO. 2004;:1–9.http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf
108 WHO. Treatment of Tuberculosis: guidelines 4th edition. WHO 2009;:WHO/HTM/TB/2009.4.
109 WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Heal Organ 2014;B:WHO/HTM/TB/2014.11.
110 WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update. World Heal Organ 2011;:WHO/HTM/TB/2008.402.
111 WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: 2014. http://www.who.int/tb/publications/pmdt_companionhandbook/en/
112 Xu H-B, Jiang R-H, Xiao H-P. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2012;18:1104–10. doi:10.1111/j.1469-0691.2011.03716.x
113 Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015;7:603–15. doi:10.3978/j.issn.2072-1439.2015.03.10
114 Zhu M, Burman WJ, Jaresko GS, et al. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001;21:1037–45.http://www.ncbi.nlm.nih.gov/pubmed/11560193 (accessed 4 Sep2013).
115 Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002;82:91–6.http://www.ncbi.nlm.nih.gov/pubmed/12356460 (accessed 26 Apr2014).
116 British National Formulary For Children. British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, and Neonatal and Paediatric Pharmacists Group 2013. www.bnfc.org
117 Summary of Product Characteristics. Electron. Med. Compend. Datapharm Commun. Ltd. http://emc.medicines.org.uk
118 Treatment of Tuberculosis: Thioacetazone. People’s Friendsh. Univ. Russ. Fac. Med. http://main.rudn.ru/_new/russian/win/tub1/tubeng2012/05_treat/05_1_7_treat_tiacet.htm
119 British National Formulary. The British Medical Association and the Royal Pharmaceutical Society 2013. www.bnf.org
1 Alffenaar J-WC, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010;49:559–65. doi:10.2165/11532080-000000000-00000
2 Alliance G, Development TBD, Alliance TB, et al. Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children. WHO 2017;:0–1.
3 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839–54. doi:10.1007/s40265-014-0222-8
4 Anon. Prothionamide. Tuberculosis (Edinb) 2008;88:139–40. doi:10.1016/S1472-9792(08)70020-9
5 Anon. Rifapentine. Tuberculosis (Edinb) 2008;88:155–8. doi:10.1016/S1472-9792(08)70025-8
6 Anon. Levofloxacin. Tuberculosis (Edinb) 2008;88:119–21. doi:10.1016/S1472-9792(08)70013-1
7 Anon. Moxifloxacin. Tuberculosis (Edinb) 2008;88:127–31. doi:10.1016/S1472-9792(08)70016-7
8 Anon. Clofazimine. Tuberculosis (Edinb) 2008;88:96–9. doi:10.1016/S1472-9792(08)70006-4
9 Anon. Cycloserine. Tuberculosis (Edinb) 2008;88:100–1. doi:10.1016/S1472-9792(08)70007-6
10 Anon. TMC-207. Tuberculosis (Edinb) 2008;88:168–9. doi:10.1016/S1472-9792(08)70029-5
11 Anon. A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong. Tubercle 1968;49:243–80.http://www.ncbi.nlm.nih.gov/pubmed/4179210 (accessed 4 Sep2013).
12 Anon. Clarithromycin. Tuberculosis (Edinb) 2008;88:92–5. doi:10.1016/S1472-9792(08)70005-2
13 Anon. Ethambutol. Tuberculosis (Edinb) 2008;88:102–5. doi:10.1016/S1472-9792(08)70008-8
14 Anon. Rifampin. Tuberculosis (Edinb) 2008;88:151–4. doi:10.1016/S1472-9792(08)70024-6
15 Anon. Capreomycin. Tuberculosis (Edinb) 2008;88:89–91. doi:10.1016/S1472-9792(08)70004-0
16 Anon. Para-aminosalicylic acid. Tuberculosis (Edinb) 2008;88:137–8. doi:10.1016/S1472-9792(08)70019-2
17 Anon. Pyrazinamide. Tuberculosis (Edinb) 2008;88:141–4. doi:10.1016/S1472-9792(08)70021-0
18 Anon. Linezolid. Tuberculosis (Edinb) 2008;88:122–5. doi:10.1016/S1472-9792(08)70014-3
19 Anon. Streptomycin. Tuberculosis (Edinb) 2008;88:162–3. doi:10.1016/S1472-9792(08)70027-1
20 Anon. Amikacin. Tuberculosis (Edinb) 2008;88:87–8. doi:10.1016/S1472-9792(08)70003-9
21 Anon. Isoniazid. Tuberculosis (Edinb) 2008;88:112–6. doi:10.1016/S1472-9792(08)70011-8
22 Anon. Rifabutin. Tuberculosis (Edinb) 2008;88:145–7. doi:10.1016/S1472-9792(08)70022-2
23 Ashley, C and Currie A, editor. The Renal Drug Handbook. 3rd ed. Radcliffe Medical Press, Oxford 2009.
24 ASHP. AHFS Drug Information. Am. Soc. Heal. Pharm. Bathesda, USA. 2011.
25 Auclair B, Nix DE, Adam RD, et al. Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids. Antimicrob Agents Chemother 2001;45:810–4. doi:10.1128/AAC.45.3.810
26 Aventis. Priftin® (rifapentine) tablets prescribing information (dated Feb 2002). In: Montvale N, ed. Physicians’ desk reference 5th edition. Medical Economics Company Inc 2003. 763–6.
27 Banerjee S, Narayanan M, Gould K. Monitoring aminoglycoside level. BMJ 2012;345:e6354.http://www.ncbi.nlm.nih.gov/pubmed/23044986 (accessed 24 Aug2013).
28 Black HR, Griffith RS, Peabody AM. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann N Y Acad Sci 1966;135:974–82.http://www.ncbi.nlm.nih.gov/pubmed/5220250 (accessed 19 Aug2013).
29 Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015;191:1058–65. doi:10.1164/rccm.201407-1264OC
30 Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 2016;3099:1–11. doi:10.1016/S1473-3099(16)30274-2
31 Bolhuis MS, van Altena R, Uges DRA, et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010;54:5418–9. doi:10.1128/AAC.00757-10
32 Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013;42:1614–21. doi:10.1183/09031936.00001913
33 Cabrera-rivero JL, Vargas-vasquez DE, Gao M, et al. new england journal. 2012;:2151–60.
34 Caminero JA. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013. Int Union Against Tuberc Lung Dis 2013.
35 Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005;49:2816–21. doi:10.1128/AAC.49.7.2816-2821.2005
36 Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994;3:267–74. doi:10.1016/0924-8579(94)90054-X
37 Chaulet P, Raviglione M, Bustreo F. Epidemiology, control and treatment of multidrug-resistant tuberculosis. Drugs 1996;52 Suppl 2:103-7-8.http://www.ncbi.nlm.nih.gov/pubmed/8869846 (accessed 19 Aug2013).
38 Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity--a case report. Lepr Rev 1995;66:63–8.http://www.ncbi.nlm.nih.gov/pubmed/7731343 (accessed 6 Nov2013).
39 Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447–54. doi:10.5588/ijtld.11.0451
40 Dannemann B, Bakare N, Marez T De, et al. QTcF prolongation in a Phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine. 52nd Intersci Conf Antimicrob Agents Chemother 2012.
41 Dauby N, Muylle I, Mouchet F, et al. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011;30:812–3. doi:10.1097/INF.0b013e3182154b05
42 De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013;41:1386–92. doi:10.1183/09031936.00124312
43 Devine B. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650–655.
44 Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284–93. doi:10.1093/jac/dks389
45 Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284–93. doi:10.1093/jac/dks389
46 Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271–6. doi:10.1128/AAC.06126-11
47 Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986–93. doi:10.1016/S0140-6736(12)61080-0
48 Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723–32. doi:10.1056/NEJMoa1313865
49 Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397–405. doi:10.1056/NEJMoa0808427
50 Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001;33:466–9.http://www.ncbi.nlm.nih.gov/pubmed/11450868 (accessed 24 Aug2013).
51 Durrant JD, Campbell K FS et al. Ototoxicity Monitoring. 2009. http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines.pdf
52 Dutta BS, Hassan G, Waseem Q, et al. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis 2012;16:141. doi:10.5588/ijtld.11.0388
53 Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516–28. doi:10.1183/09031936.00073611
54 Garcia-Prats, AJ Donald, PR Hesseling, AC Schaaf H. Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines. World Heal Organ Published Online First: 2013.www.who.int/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf
55 Goh TL, Towns CR, Jones KL, et al. Extensively drug-resistant tuberculosis: New Zealand’s first case and the challenges of management in a low-prevalence country. Med J Aust 2011;194:602–4.http://www.ncbi.nlm.nih.gov/pubmed/21644877 (accessed 24 Aug2013).
56 Gonzalo X, Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 2013;68:366–9. doi:10.1093/jac/dks395
57 Gordin F, Bliven-sizemore E, Hackman J, et al. new england journal. 2011;:2155–66.
58 Gynaecology RC of O and. Drug Interactions with Hormonal Contraception. Faculty of Sexual & Reproductive Healthcare Clinical Guidance 2011. http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf
59 Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis 2008;12:967–71.http://www.ncbi.nlm.nih.gov/pubmed/18647459 (accessed 21 Feb2017).
60 Hoc A, Management A, Ototoxic R, et al. Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy. Published Online First: March 1994. doi:10.1044/policy.GL1994-00003
61 Hutchison TA SD& AM. Drugdex System Internet version Micromedex Inc. Greenwood Village, Colorado.
62 Janssen. Compassionate Use Program of TMC207 in Patients with Extensively Drug Resistant (XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection. Guidel physicians Pharm 2012.
63 Janssen. Anti-Infective Drugs Advisory Committee Meeting Briefing Document: TMC207 (bedaquiline): Treatment of Patients with MDR-TB. NDA 2012;:204–384.
64 Janssen. SirturoTM U.S. Food and Drug Administration bedaquiline package insert. 2012.http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html
65 Jindani A, Harrison TS, Nunn AJ, et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N Engl J Med 2014;371:1599–608. doi:10.1056/NEJMoa1314210
66 Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139–45.http://www.ncbi.nlm.nih.gov/pubmed/18230245 (accessed 4 Sep2013).
67 Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508–18. doi:10.1056/NEJMoa1201964
68 Lee M, Song T, Kim Y, et al. Linezolid for XDR-TB — Final Study Outcomes. N Engl J Med 2015;373:290–1. doi:10.1056/NEJMc1500286
69 Lehmann CR, Garrett LE, Winn RE, et al. Capreomycin kinetics in renal impairment and clearance by hemodialysis. Am Rev Respir Dis 1988;138:1312–3. doi:10.1164/ajrccm/138.5.1312
70 Loeffler A et al. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd ed. Curry International Tuberculosis Center and California Department of Public Health 2011.
71 Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34:387–93. doi:10.1183/09031936.00009509
72 Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557–70. doi:10.1136/thx.2009.133173
73 National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. 2011.
74 Organisation WH. Interim guidance on the use of bedaquiline to treat MDR-TB. World Heal Organ 2012;:WHO/HTM/TB/2013.6.
75 Orgnaisation WH. Statement on the position of the stop TB department with regard to thioacetazone + isoniazid within context of the who model list of essential medicines. World Heal. Organ. 2004.http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf
76 Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012;16:558–60. doi:10.5588/ijtld.11.0414
77 Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253–62.http://www.ncbi.nlm.nih.gov/pubmed/8231410 (accessed 19 Aug2013).
78 Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999;159:932–4. doi:10.1164/ajrccm.159.3.9807131
79 Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169–83.http://www.ncbi.nlm.nih.gov/pubmed/12381217 (accessed 4 Sep2013).
80 Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538–44. doi:10.1086/420742
81 PfizerTrecator®. U.S. Physician Prescribing Information. PfizerTrecator®. 2007;:1–8.http://labeling.pfizer.com/showlabeling.aspx?id=473 (accessed 28 Aug2013).
82 Pharmaceuticals K. Personal communication: Capreomycin and intravenous administration.
83 Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011;38:888–94. doi:10.1183/09031936.00176610
84 Prasad R, Verma SK, Sahai S, et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci;48:183–6.http://www.ncbi.nlm.nih.gov/pubmed/18610675 (accessed 24 Aug2013).
85 Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012;16:1588–93. doi:10.5588/ijtld.12.0322
86 Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27–35. doi:10.1016/S1473-3099(12)70264-5
87 Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831–5. doi:10.1128/AAC.01204-07
88 Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011;12:31–8. doi:10.1016/j.prrv.2010.09.010
89 Schilling R. Appropriate monitoring for prolonged QT. Unpubl Commun 2013.
90 Seddon J a, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012;186:953–64. doi:10.1164/rccm.201206-1001CI
91 Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393–400. doi:10.1183/09031936.00125812
92 Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430–42. doi:10.1183/09031936.00022912
93 Soumakis SA, Berg D, Harris HW. Hypothyroidism in a Patient Receiving Treatment for Multidrug‐Resistant Tuberculosis. Clin Infect Dis 1998;27:910–1. doi:10.1086/517171
94 Srivastava S, Peloquin C a, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449–53. doi:10.1183/09031936.00073213
95 STOP TB Partnership Child Health Subgroup WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children. Int J Tuberc Lung Dis 2006;10:1205–11.http://www.ncbi.nlm.nih.gov/pubmed/17131777 (accessed 4 Sep2013).
96 STOP TB Partnership, Child Health Subgroup, World Health Organisation, Geneva S. Rapid advice: Treatment of Tuberculosis in Children. WHO 2010;:WHO/HTM/TB/2010.13.
97 Sturdy A, Goodman A, José RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815–20. doi:10.1093/jac/dkr221
98 Sweetman S M, editor. The Complete Drug Reference, online edition. Pharm. Press. London.
99 Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45:161–70. doi:10.1183/09031936.00035114
100 Thee S, Seifart HI, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother 2011;55:4594–600. doi:10.1128/AAC.00379-11
101 Thee S, Zöllner EW, Willemse M, et al. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011;15:1191–3, i. doi:10.5588/ijtld.10.0707
102 Tucker H. Dear Healthcare Professional Letter. 2005.http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164879.pdf
103 WHO. Guidelines on the management of latent tuberculosis infection. World Heal Organ 2015;WHO/HTM/TB.http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1&ua=1
104 WHO. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva World Heal Organ Published Online First: 2013.http://www.ncbi.nlm.nih.gov/books/NBK154134/
105 WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis: An interim policy guidance. World Heal Organ Published Online First: 2014.http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1
106 WHO. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. World Heal Organ 2006;:WHO/HTM/ TB/2006.371, WHO/FCH/CAH/2006.7.
107 WHO. STATEMENT ON THE POSITION OF THE STOP TB DEPARTMENT WITH REGARD TO THIOACETAZONE + ISONIAZID WITHIN CONTEXT OF THE WHO MODEL LIST OF ESSENTIAL MEDICINES. WHO. 2004;:1–9.http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf
108 WHO. Treatment of Tuberculosis: guidelines 4th edition. WHO 2009;:WHO/HTM/TB/2009.4.
109 WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Heal Organ 2014;B:WHO/HTM/TB/2014.11.
110 WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update. World Heal Organ 2011;:WHO/HTM/TB/2008.402.
111 WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: 2014. http://www.who.int/tb/publications/pmdt_companionhandbook/en/
112 Xu H-B, Jiang R-H, Xiao H-P. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2012;18:1104–10. doi:10.1111/j.1469-0691.2011.03716.x
113 Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015;7:603–15. doi:10.3978/j.issn.2072-1439.2015.03.10
114 Zhu M, Burman WJ, Jaresko GS, et al. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001;21:1037–45.http://www.ncbi.nlm.nih.gov/pubmed/11560193 (accessed 4 Sep2013).
115 Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002;82:91–6.http://www.ncbi.nlm.nih.gov/pubmed/12356460 (accessed 26 Apr2014).
116 British National Formulary For Children. British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, and Neonatal and Paediatric Pharmacists Group 2013. www.bnfc.org
117 Summary of Product Characteristics. Electron. Med. Compend. Datapharm Commun. Ltd. http://emc.medicines.org.uk
118 Treatment of Tuberculosis: Thioacetazone. People’s Friendsh. Univ. Russ. Fac. Med. http://main.rudn.ru/_new/russian/win/tub1/tubeng2012/05_treat/05_1_7_treat_tiacet.htm
119 British National Formulary. The British Medical Association and the Royal Pharmaceutical Society 2013. www.bnf.org